Deborah Cooper was part-time managing director of Antaria from September 2010 to February 2012. Dr Cooper joined as a non-executive director earlier in 2010 after more than 15 years commercial management and scientific experience in the biotech industry, including as general manager/chief scientific officer of CollTech Australia, where she was responsible for product development, the development of key strategic alliances, the successful commercialisation of new products, and driving sales and shareholder returns. She continued briefly at Antaria (later Advanced Nano Technologies) as an NED before resigning in August 2012. Dr Cooper has been a consultant to the sector since that time. Dr.
Cooper has previously worked for tissue engineering
companies such as Clinical Cell Culture (C3) and Verigen
Australia (Genzyme subsidiary).
